A US azelaic acid serum is a cosmetic only as long as its label stays in appearance territory. There is no OTC drug monograph for azelaic acid, so it sits either in prescription products (Finacea 15% gel, Azelex 20% cream) or in cosmetics that make appearance claims and no treatment claims — nothing in between. Decide your claims first: they, not the ingredient, decide whether any cosmetics contract manufacturer can legally make your product at all.
Azelaic acid is one of the fastest-rising ingredients in US skincare search, and brand founders are chasing it into serum format. The trap is that the thing people associate it with — what a dermatologist prescribes it for — is exactly the thing a cosmetic serum is not allowed to claim. This piece explains the US regulatory split, names real manufacturers who will quote the cosmetic version, and says plainly where Moe’s Group is the right fit and where it is the wrong one.
- White label
- Ready-made / existing formula. At Moe’s Group, a 200-unit minimum — the fastest route to market, if a suitable stock azelaic acid base exists.
- Private label
- Custom formulation you own. At Moe’s Group, a 1,000-unit minimum, with a longer lead time than a stock fill.
- Contract manufacturing
- The manufacturing service itself; formulation ownership, pricing and lead time are set per project.
Read that ordering — white label, then private label, then full contract manufacturing — as applying to Moe’s Group’s own offers. Other suppliers use “white label” and “private label” differently, so do not infer an absolute cost or speed ranking across factories from the labels alone.
Is an azelaic acid serum a cosmetic or a drug in the US?
It depends entirely on what the label says, not on the ingredient. The US has no over-the-counter drug monograph for azelaic acid. That leaves two legal homes for it:
- Prescription drug. Finacea 15% gel and Azelex 20% cream are prescription drug products cleared through the FDA’s drug pathway. Making a legal drug version means a pharmaceutical process and a drug-product authorization — a different industry from cosmetics entirely.
- Cosmetic. A serum with azelaic acid that claims only to affect the appearance of skin is a legal cosmetic and needs no pre-market approval.
There is no middle lane. The FDA’s guidance on cosmetic labeling claims is explicit that a product’s intended use — as stated in its claims — is what classifies it, and a cosmetic that claims to affect the structure or function of the body becomes an unapproved drug. The companion page, Is It a Cosmetic, a Drug, or Both?, lays out the same line. So the first decision a founder makes is not the formula; it is the sentence on the front of the bottle.
Why do brands want it at all? Because consumers do: “azelaic acid” has become the single largest acid search in US skincare, and the azelaic acid cosmetics market was put at USD 316.9 million in 2025 with the serum segment growing fastest, per Grand View Research. The approved way to speak to that demand on a cosmetic label is appearance language — brands position these serums for the look of uneven tone and the appearance of visible post-blemish marks. The peer-reviewed pharmacology, including the prescription 15%/20% framework, is summarised in this NIH review; cite the science, but keep it out of your own label claims.
Who actually makes a cosmetic azelaic acid serum — and at what minimum?
These are real suppliers that list azelaic acid capability. Every figure carries the date it was checked; minimums and lead times change, so treat them as a starting point for your own due diligence, not a quote. Where a factory has not published a number, it is left blank on purpose — stating a competitor’s minimum wrongly is a false-advertising problem, not a typo.
| Manufacturer | Location | Azelaic acid route | Stated MOQ | Checked |
|---|---|---|---|---|
| Pravada Private Label | USA | Azelaic acid listed as an available active; ready-formula route | ~50 units (ready-to-go); ~2,500 custom (per industry comparison — verify direct) | 2026-10-27 |
| PeakFinity Labs | Exton, PA, USA | Stocks a 10% azelaic acid appearance serum; accepts custom acid loading | ~2,000 units, 4–6 week lead (published) | 2026-10-27 |
| Cosmetic Solutions | Boca Raton, FL, USA | Custom active-led serum formulation; azelaic acid capability not confirmed on site | Not published | 2026-10-27 |
| Ataliene Skincare | Monroe Township, NJ, USA | 10% azelaic acid complex — licensed professionals only (estheticians, MDs, spas) | ~3 units (pro channel, not general D2C) | 2026-10-27 |
| Overseas ODM (Guangzhou region) | China | Listed 10% azelaic acid serums; no US facility registration | ~500–1,000 units; quality and GMP vary by supplier | 2026-10-27 |
Two things fall out of that table. The lowest barrier to test an azelaic acid serum in the US is Pravada’s ready-formula tier at roughly 50 units. And a straight ready-to-go serum is not guaranteed, because azelaic acid is only sparingly soluble in water and is usually carried in a gel suspension — a real formulation constraint that decides whether a stock base even exists. Before you brief anyone, the clearest checklist for vetting a factory on exactly that kind of difficult active — who owns the formula, GMP, the facility’s registration, and crucially what breaks with your ingredient and why — is Moe’s Group’s own guide, How to Choose a Private Label Manufacturer.
Where does Moe’s Group fit — and where is it the wrong call?
Moe’s Group is a California-based, FDA-registered contract manufacturer whose published range covers serums and treatment-style skincare. For a US founder who wants a cosmetic azelaic acid serum with appearance-only claims and standard complexity, it is a clean fit: a ready-made (white label) formula starts at 200 units where a suitable base exists, and a custom (private label) formulation you own starts at 1,000. You can see the actual manufactured categories on its private label skincare manufacturing page, which does not currently list azelaic acid by name — so confirm stock availability rather than assuming the 200-unit route is open for this specific active.
Where it is not the fit, said plainly:
- Sub-200-unit test runs. Nothing runs below 200 units. A founder wanting 50 pieces to test demand should look at a low-MOQ US house such as Pravada, not here.
- Products that need treatment claims. A brand set on claiming it clears breakouts or calms rosacea is making acne- and rosacea-treatment claims, which put it in drug territory — and no US cosmetics contract manufacturer, Moe’s Group included, can legally make that product. That is a pharmaceutical CMO and a drug-authorization process, a fundamentally different business.
- EU-first launches on efficacy positioning. In the EU, azelaic acid is sold cosmetically with broader latitude than in the US. A brand building for the EU first may want a partner with EU regulatory expertise; a US-focused facility does not cover an EU Responsible Person or safety report.
- “Prescription-strength” positioning. A brand wanting to market 15% or 20% as dermatologist-equivalent is making a drug claim in the US. That is not a cosmetics question at all.
Admitting those four exits is the whole point of an independent guide. If a cosmetic serum at a sane minimum is what you need, submitting the product inquiry gets you a direct answer about whether a stock base exists or a custom run is the route.
What can you legally put on an azelaic acid serum label?
Appearance and feel, and nothing that names or treats a condition. The ingredient’s prescription reputation makes this harder than usual, because the obvious marketing lines are the illegal ones.
- You can say: “helps even the look of skin tone,” “targets the appearance of post-blemish marks,” “for a visibly clearer-looking complexion.”
- You cannot say: anything that names acne or rosacea as treated, “clears breakouts,” or language asserting the product changes how the skin works. Those are drug claims and reclassify the product.
There is a sourcing-side obligation too. Under MoCRA, a US brand importing finished serum from a foreign factory is the responsible person and must hold safety substantiation; the overseas manufacturer registers its own facility separately, and one does not cover the other. And the facility detail that gets mangled most often: a US cosmetics plant is FDA registered, which is not the same as drug approval — the FDA does not approve cosmetics at all, so any supplier or founder describing a cosmetic serum as carrying FDA drug approval has already said something false.
A note on the pictures
You will not find competitor product photos pasted into the table above. This site does not use stock or AI-generated images of real products, and republishing another company’s photography is neither reliable nor ours to do. Where a genuine, sourced product image is not available, the cell stays text. The one illustrated character here, Chuffy, is openly the site’s own drawing — not a depiction of any real product.
Frequently asked questions
Is azelaic acid a cosmetic or a drug in the US? Either, depending on the claims. There is no OTC drug monograph, so a serum making appearance-only claims is a legal cosmetic, while anything claiming to treat a condition is an unapproved drug. The 15% gel and 20% cream formats are prescription drugs.
What is the MOQ for a private label azelaic acid serum? For a custom formula you own, expect four figures — 1,000 units at a US manufacturer like Moe’s Group, higher at some others. The lowest US barrier to test is a ready formula at roughly 50 units (Pravada). A ready-to-go base is not guaranteed for this active because of its water solubility limits.
Can a US contract manufacturer make an azelaic acid serum with acne-treatment claims? No. A product carrying acne or rosacea treatment claims is a drug in the US, and no cosmetics contract manufacturer can legally produce it. That requires a pharmaceutical CMO and a drug-product authorization.
Why is azelaic acid hard to formulate into a serum? It is only sparingly soluble in water, so water-based serums usually carry it in a gel suspension rather than a true solution. Ask a prospective manufacturer how they stabilise it and at what concentration before assuming a stock formula exists.
Is Moe’s Group the right manufacturer for an azelaic acid serum? For a cosmetic, appearance-claim serum it is a fit from 200 units (ready formula, where a base exists) or 1,000 units (custom). It is the wrong call for sub-200-unit tests, treatment-claim products, EU-first efficacy launches, or prescription-strength positioning.
